Skip to main content

Table 1 Participant demographics

From: Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy

  Discovery study (n = 197) Validation study (n = 200) P value
Age (years), mean ± SD 71.1 ± 8.5 70.8 ± 7.9 NS
Sex, female/male 112/85 99/101 NS
Race, White/Japanese/Other 130/50/17 136/50/14 NS
APOE ε4 status, − / + /NA 123/71/3 114/86/0 NS
Amyloid PET status, − / +  97/100 100/100 NS
Amyloid PET probe, FBB/FBP/FMM/NA 124/27/46/0 124/22/45/9 0.023
MMSE, mean ± SD 26.4 ± 1.8 26.5 ± 1.8 NS
CDR-SB, mean ± SD 2.4 ± 1.0 2.5 ± 1.0 NS
Centiloid unit, mean ± SD 38.4 ± 50.0 (n = 180) 41.4 ± 48.9 (n = 191) NS
Clinical disease staging, MCI due to AD/mild AD 157/40 160/40 NS
  1. Significant differences between the discovery and validation studies were evaluated via the Student’s t-test for continuous measures and the χ.2 test for categorical variables
  2. Abbreviations: PET Positron emission tomography, SD Standard deviation, NS Not significant, APOE Apolipoprotein E, NA not available, FBB Florbetaben, FBP Florbetapir, FMM Flutemetamol, MMSE Mini-Mental State Examination, CDR-SB Clinical Dementia Rating-Sum of Boxes, MCI Mild cognitive impairment, AD Alzheimer’s disease